MedScout, a commercial intelligence platform for MedTech companies, announced a $10 million growth funding round led by Fulcrum Equity Partners with participation from existing investors Live Oak Venture Partners and Stage 2 Capital.
The funding round more than doubled the company’s valuation compared with its Series A round and will be used to accelerate the development of MedScout’s artificial intelligence capabilities while supporting the growing demand from enterprise customers. The Austin-based company said enterprise revenue has grown threefold since its Series A in July 2024 as medical technology companies adopt AI-driven tools to translate commercial strategies into execution by field sales teams.
MedScout simultaneously introduced Strategies, a new set of AI agents designed to help MedTech commercial teams identify high-value opportunities and deploy targeted territory plans. These AI agents analyze referral networks, procedure volumes, payer dynamics, and other healthcare market data to prioritize physicians, facilities, and accounts for sales representatives.
The launch aims to address a longstanding gap in MedTech sales operations where corporate commercial strategies often fail to translate into clear actions for field representatives. According to the company, many reps currently rely on fragmented information sources, such as search engines, outdated spreadsheets, or data platforms that lack the contextual insights needed to determine which providers and facilities to prioritize.
Each AI Strategy agent is built around a company’s specific commercial context and definition of ideal targets, incorporating industry insights and patterns from MedScout’s work with hundreds of MedTech commercial teams. The system then generates prioritized territory plans that sales representatives can use to guide outreach and relationship development with providers and healthcare systems.
MedScout said adoption of the AI agents has accelerated rapidly since customers gained access to Strategies in late 2025. In January, customers deployed 81 percent more unique AI agents compared with the previous month, reflecting early traction across enterprise sales organizations. Monthly active sales representatives using the platform have also increased 135 percent month over month as commercial teams expand their use of the new tools.
The company reports that enterprise MedTech organizations increasingly rely on MedScout to help coordinate large and geographically distributed sales teams around the most promising opportunities. The AI platform integrates with existing customer relationship management systems and other commercial tools to deliver insights directly into sales workflows.
MedScout said the technology can support a variety of commercial use cases across the MedTech industry. For example, surgical robotics companies can identify orthopedic surgeons performing high volumes of traditional knee replacement procedures who may be strong candidates for robotic-assisted surgery adoption. Diagnostic imaging companies can pinpoint physicians whose referral patterns suggest an opportunity to shift biopsy procedures to priority facilities. Cardiology device companies can identify hospitals experiencing declining structural heart procedure volumes despite maintaining high cardiac catheterization capacity.
Founded to serve medical device and diagnostics companies, MedScout’s platform analyzes real-world healthcare data, including procedure volumes, referral networks, and payer dynamics, to help commercial teams identify the clinicians and facilities most likely to adopt new technologies.
MedScout said that hundreds of MedTech companies now use the platform to align commercial strategy with field execution, as the industry increasingly turns to AI-driven analytics to improve sales performance and accelerate the adoption of medical innovations.
KEY QUOTES:
“MedScout is tackling one of the most pressing challenges in MedTech: turning company strategy into revenue performance. What they’ve built combines commercial expertise and AI to solve that problem in a highly actionable way that’s unique to each customer. This is the future of how companies put AI to work, and it’s why we’re doubling down on our investment in MedScout.”
Philip Lewis, Partner at Fulcrum Equity Partners
“MedTech companies spend months developing commercial strategies that don’t make it to the field as intended. MedScout bridges that gap by translating commercial priorities into clear, territory-specific actions. Sales reps know which providers to prioritize and how to build and expand those relationships. In January, our customers deployed 81% more unique AI agents than the month before — evidence that sales teams are seeing value quickly and building on early success.”
Skylar Talley, Co-founder and CEO of MedScout
“Everything we do is in service of better patient outcomes, and that starts with getting our innovations into the hands of the right clinicians. MedScout has been a strategic partner in helping our field teams identify, prioritize, and connect with the facilities and providers where our technologies can have the greatest impact. The result is stronger commercial performance and more patients benefiting from precision care. We’re proud to work with MedScout and excited for this next phase of our partnership.”
Meraj Khan, Chief Marketing Officer, Surgical Innovations at GE Healthcare
